Please login to the form below
Alzheimer’s disease: reviewing the immediate treatment horizon
Account Manager Stuart Goodman takes a look at some of the promising categories of Phase 3 treatments that could soon be available to patients with Alzheimer's disease.
With a current market valuation at $6.5 billion, and a projected direct medical cost of $1.1 trillion by 2050, Alzheimer’s disease (AD) is an area of huge unmet need.¹ There is enormous commercial potential for pharmaceutical companies to address the challenge of AD sooner rather than later, and we see many contenders racing to be the first to do so.Unfortunately, the complexity of the disease has meant that many recent AD trials have been unsuccessful.
However, the learnings from these ‘failures’ have paved the way for the robust pipeline of treatments that could potentially be coming to market in the next five years.
A recent article by BLH Consultant David Cooney explored the bleak history of Alzheimer’s disease trial failures since the turn of the century. In it, he highlighted how, despite continued investment by pharmaceutical companies into AD treatment research, AD sufferers still only have 5 FDA-approved treatments to choose from, and even these are only capable of slowing the progression of disease symptoms.
However, every trial that has been unsuccessful has been a guiding hand to the scientific community, allowing those working extensively in the disease area to progress our understanding and develop new molecules for application in new trials and investigations. In this article, Account Manager Stuart Goodman takes a look at some of the promising categories of Phase 3 treatments that could soon be available to patients with AD.
Crenezumab, gantenerumab, and solanezumab are all involved in additional prospective longitudinal investigations – the Alzheimer’s Prevention Initiative (Phase 2), the Dominantly Inherited Alzheimer Network study (Phase 2/3), and the Anti-Amyloid Treatment in AD Prevention Trial (Phase 3) respectively. These investigations are ongoing, and will examine whether anti-amyloid drugs can prevent or delay disease onset in individuals with a high chance of developing AD (as determined by genetic predisposition or PET brain scans). They represent an important shift of research focus to earlier in the disease pathway, and will go a long way toward supporting or refuting the concept of the amyloid hypothesis.
References:![]()
![]()
![]()
However, the learnings from these ‘failures’ have paved the way for the robust pipeline of treatments that could potentially be coming to market in the next five years.
A recent article by BLH Consultant David Cooney explored the bleak history of Alzheimer’s disease trial failures since the turn of the century. In it, he highlighted how, despite continued investment by pharmaceutical companies into AD treatment research, AD sufferers still only have 5 FDA-approved treatments to choose from, and even these are only capable of slowing the progression of disease symptoms.
However, every trial that has been unsuccessful has been a guiding hand to the scientific community, allowing those working extensively in the disease area to progress our understanding and develop new molecules for application in new trials and investigations. In this article, Account Manager Stuart Goodman takes a look at some of the promising categories of Phase 3 treatments that could soon be available to patients with AD.
The continued focus on a beta-amyloid solution
Whilst there is increasing evidence that AD is a complex and multi-factorial disease, many scientists continue to believe that beta-amyloid (Aβ) is the main pathogenic factor responsible for the degenerative changes that occur in the brain during AD. Consequently, manipulating the amount of Aβ in the brain still represents one of the most attractive approaches for disease intervention in AD. We can see this reflected in the five-year Phase 3 pipeline, where Aβ immunotherapy drugs, small-molecule BACE inhibitors and anti-Aβ aggregation agents are all undergoing late stage testing.Crenezumab, gantenerumab, and solanezumab are all involved in additional prospective longitudinal investigations – the Alzheimer’s Prevention Initiative (Phase 2), the Dominantly Inherited Alzheimer Network study (Phase 2/3), and the Anti-Amyloid Treatment in AD Prevention Trial (Phase 3) respectively. These investigations are ongoing, and will examine whether anti-amyloid drugs can prevent or delay disease onset in individuals with a high chance of developing AD (as determined by genetic predisposition or PET brain scans). They represent an important shift of research focus to earlier in the disease pathway, and will go a long way toward supporting or refuting the concept of the amyloid hypothesis.
References:
- Qian X, et al. Nature Reviews Drug Discovery. 2015;14:675-76.
Download the full article from Blue Latitude Health
Company Details
Blue Latitude Health
+44 203 328 1840
Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom
Latest content on this profile
- Three strategies for managing loss of exclusivity successfully
- Consultant, Claire Taylor explains why you should be strategically planning your LOE strategy years in advance.
Blue Latitude Health
- What does the future hold for Medical Affairs?
- Lori Lush, Head of Fishawack Medical, reveals why she’s driven to tell impactful scientific stories, the benefits of cross-functional collaboration, and the trends she predicts for the next five years.
Blue Latitude Health
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the life sciences industry can do to rebuild trust.
Blue Latitude Health
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and Senior Consultant Craig Moore explore the benefits of using real-world evidence and the common pitfalls life science companies should avoid.
Blue Latitude Health
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of this lost time for patients?
Blue Latitude Health
- Unpacking rare diseases in the first edition of Delta magazine
- Fishawack Health launches Delta magazine with a deep dive into rare disease commercialization
Blue Latitude Health
